NCT04988815View on ClinicalTrials.gov

Ropeginterferon Alfa 2b for Early Myelofibrosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
Primary Myelofibrosis, Prefibrotic StageMyelofibrosis
Interventions
DRUG

Ropeginterferon alfa-2b

Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards

Trial Locations (1)

Unknown

RECRUITING

Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER